- State of the current market and impact on manufacturing cell and gene therapies
- Key factors to consider when scaling up a facility for advanced medicines
- Make vs. Buy and the advantages and challenges of both solutions given the current market
Moderator:
VP of Strategy
Project Farma
Adam Pfeiffer is the Vice President of Strategy at Project Farma. In his role, Adam drives overall business strategy, aligning with operations, marketing, and business development groups in growing the firm’s global life sciences partnerships.With 16+ years of life sciences consulting experience, Adam has supported countless drug manufacturers in bringing life-saving therapies to the market, with an emphasis on engineering and qualification in the advanced therapy and large-molecule biologics space. He has a degree in Chemical Engineering from Colorado State University.
Panelists:
EVP
Project Farma
Tony Khoury is an experienced industry leader in life sciences, specifically, biologics and advanced therapies. As a member of the Project Farma leadership team, Tony has spearheaded the firm’s growth in the biologics and most recently next generation medicines. Tony has extensive experience with small and large molecules including biologics, biosimilars, and cell and gene therapies. He has worked with small and large life science organizations including startups, academic centers, financial institutions and CMOs/CROs. He has led global programs greater than $350+ million in the following disciplines: project management, turnkey facility builds, automation, validation, engineering and serialization track and trace. Recently, Tony has pioneered the industrialization of advanced therapies including two FDA-approved cell and gene therapies. Tony has led the creation of Project Farma’s Advanced Therapy Manufacturing Playbook which has helped develop the largest cell and gene therapy manufacturing footprint in the world.
VP, Technical Operations
BioNTech
Chief Technical Officer
TCR² Therapeutics
Peter Olagunju serves as the Chief Technical Officer of TCR². He brings over 20 years of experience in cell and gene therapy, clinical development, program management, manufacturing and technical operations. Prior to joining the Company, he was Senior Vice President of Technical Operations at FerGene Inc., where he led the technical operations function for the commercialization of a gene therapy for bladder cancer. Before that, Mr. Olagunju was Vice President of Global Patient Operations at bluebird bio, Inc., where he held several roles of increasing responsibility and was the program lead and functional head of manufacturing supporting the European approval for ZYNTEGLO®, a transformational gene therapy for Transfusion dependent Thalassemia. Earlier in his career, he held senior positions in Commercial Technical Operations and served as the Head of Quality at Dendreon Corp. and ZymoGenetics, Inc. Mr. Olagunju holds an M.B.A. from the University of Washington and a B.S. in Biology from the University of Illinois at Urbana-Champaign.
